Evidence map›Paper›PMID 33767595›Full record

ArticleInternational journal of biological sciences2021

MLKL inhibits intestinal tumorigenesis by suppressing STAT3 signaling pathway.

Qun Zhao, Xinran Cheng, Jian Guo, Yun Bi, Li Kuang, Jianhua Ren, Jing Zhong, Longrui Pan, Xudong Zhang, Yang Guo and 4 more

Open access · goldAbstract read
In one paragraph

Article in International journal of biological sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Prognostic Significance and Immune Environment Analysis Using PANoptosis Molecular Clustering in Gastric Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2025
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. The Many Faces of MLKL, the Executor of Necroptosis.International journal of molecular sciences · 2023
    Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Qun ZhaoLaboratory of Inflammation and Molecular Pharmacology, Hubei Key Laboratory of Embryonic Stem Cell Research, School of Basic Medical Sciences & Biomedical Research Institute, Hubei University of Medicine, Shiyan 442000, China.
Xinran ChengLaboratory of Inflammation and Molecular Pharmacology, Hubei Key Laboratory of Embryonic Stem Cell Research, School of Basic Medical Sciences & Biomedical Research Institute, Hubei University of Medicine, Shiyan 442000, China.
Jian GuoLaboratory of Inflammation and Molecular Pharmacology, Hubei Key Laboratory of Embryonic Stem Cell Research, School of Basic Medical Sciences & Biomedical Research Institute, Hubei University of Medicine, Shiyan 442000, China.
Yun BiLaboratory of Inflammation and Molecular Pharmacology, Hubei Key Laboratory of Embryonic Stem Cell Research, School of Basic Medical Sciences & Biomedical Research Institute, Hubei University of Medicine, Shiyan 442000, China.
Li KuangDepartment of Oncology, Affiliated Dongfeng Hospital, Hubei University of Medicine, Shiyan 442000, China.
Jianhua RenDepartment of Oncology, Affiliated Dongfeng Hospital, Hubei University of Medicine, Shiyan 442000, China.
Jing ZhongLaboratory of Inflammation and Molecular Pharmacology, Hubei Key Laboratory of Embryonic Stem Cell Research, School of Basic Medical Sciences & Biomedical Research Institute, Hubei University of Medicine, Shiyan 442000, China.
Longrui PanLaboratory of Inflammation and Molecular Pharmacology, Hubei Key Laboratory of Embryonic Stem Cell Research, School of Basic Medical Sciences & Biomedical Research Institute, Hubei University of Medicine, Shiyan 442000, China.
Xudong ZhangLaboratory of Inflammation and Molecular Pharmacology, Hubei Key Laboratory of Embryonic Stem Cell Research, School of Basic Medical Sciences & Biomedical Research Institute, Hubei University of Medicine, Shiyan 442000, China.
Yang GuoLaboratory of Inflammation and Molecular Pharmacology, Hubei Key Laboratory of Embryonic Stem Cell Research, School of Basic Medical Sciences & Biomedical Research Institute, Hubei University of Medicine, Shiyan 442000, China.
Yongqiang LiuInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Shu JinDepartment of Gastroenterology, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, China.
Yan TanLaboratory of Inflammation and Molecular Pharmacology, Hubei Key Laboratory of Embryonic Stem Cell Research, School of Basic Medical Sciences & Biomedical Research Institute, Hubei University of Medicine, Shiyan 442000, China.
Xianjun YuLaboratory of Inflammation and Molecular Pharmacology, Hubei Key Laboratory of Embryonic Stem Cell Research, School of Basic Medical Sciences & Biomedical Research Institute, Hubei University of Medicine, Shiyan 442000, China.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNGuangzhou University of Chinese Medicine · CNTaihe Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mixed lineage kinase domain-like protein (MLKL) plays an important role in necroptosis, but the role and mechanism of MLKL in intestinal tumorigenesis remain unclear. Here, we found that hematopoietic- and nonhematopoietic-derived MLKL affected intestinal inflammation, but nonhematopoietic-derived MLKL primarily inhibited intestinal tumorigenesis. Loss of MLKL enhanced intestinal regeneration and the susceptibility to intestinal tumorigenesis in

Indexed as

CarcinogenesisAnimalsCase-Control StudiesColorectal NeoplasmsFemaleHumansInterleukin-6IntestinesJanus Kinase 2MaleMiceProtein KinasesRegenerationSignal TransductionSTAT3 Transcription FactorInterleukin-6interleukin-6, mouseJak2 protein, mouseJanus Kinase 2MLKL protein, humanMLKL protein, mouseProtein KinasesStat3 protein, mouseSTAT3 Transcription FactorAnti-IL-6R antibody therapy.IL-6/STAT3Intestinal tumorigenesisMLKL

Identifiers

PMID33767595
PMCPMC7975698
OpenAlexW3132796803

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.